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EDITORIAL
Fluoride and bone disease in uremia
This editorial is a review of the possible relationship
of fluoride to bone disease in uremia. Normally,
fluoride enters the body through ingestion in food and
water, though miniscule amounts may be inhaled or
absorbed through the skin [11. Soluble fluoride com-
pounds, such as sodium fluoride and sodium silico-
fluoride, are completely absorbed in the gut [2, 3]. Less
soluble compounds, including calcium fluoride and
fluorapatite (bone meal) are partially absorbed; as
much as two-thirds of ingested fluorapatite is present
in feces [4]. Total fluoride ingestion is estimated at 3
to 5 mg/day for healthy indoor workers in communities
with fluoridated drinking water [5]. Fluoridated water
generally contains 53 moles (1 part per million or
1 mg/liter) of fluoride.
Ingested fluoride is absorbed mainly in the upper
gastrointestinal tract, Trace doses of fluoride leave the
blood within minutes, concentrating principally In
bone and kidney [6]; less than l0% of labelled dose is
detectable in plasma at any time [7].
An equilibrium mechanism provides a balanced dis-
tribution of fluoride between plasma and erythrocytes
with concomitant "exchange deposition" in apatite
mineral of bones, and the relative concentration of
fluoride in blood and bone depends on the rate and
extent of fluoride excretion by the kidneys [8]. The de-
position of fluoride in bone is nonuniform. Saturation
of exchange sites is progressive, particularly in adults
who evince no net retention of fluoride [4].
Fluoride is filtered through the glomerulus and ap-
proximately 51 to 63% is reabsorbed in the tubule.
Preferential excretion of fluoride over chloride is evi-
dent leading to urinary excretion of about one-third of
absorbed fluoride in four hours [7]. Impaired renal
function decreases gut absorption of fluoride by an un-
defined mechanism [9]. Little is known about fluoride
interaction with body fluids and cellular elements,
particularly in soft tissue. Sweat losses of fluoride are
negligible.
Serum fluoride concentration is approximately
1 mole (0.02 g/ml) in normal adults [10, 11], rising
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significantly in uremic patients. In a study by Siddiqui
et al [11], serum fluoride concentration was 0.054±
0.025 g/ml in patients whose serum creatinine con-
centration was less than 3 mg/lOO ml, but was elevated
to 0.094 0.01 g/ml in patients whose creatinine was
above 3.0 mg/lOO ml. Several studies have found serum
concentration of fluoride in uremic patients hemodi-
alyzed with fluoridated water to be about ten times
normal [10—13]. As will be discussed in the following,
the potential for accumulation of toxic amounts of
fluoride from fluoridated water during dialysis is well
appreciated.
Effects on bone
A strong chemical bonding of fluoride to calcium
and phosphorus accounts for its deposition in hard
tissues, especially bone, teeth, nails, hair and calcified
blood vessels. Similar chemical affinity for other
cations, principally magnesium and manganese, has
been suggested as explanation for fluoride's inter-
ference in enzyme function [14].
Stimulation of osteoblastic activity by fluoride [15]
results in formation of poorly mineralized osteoid-
simulating osteomalacia. Mineralization of fluoride-
induced osteoid follows treatment with vitamin D and
large doses of calcium [16]. Faccini reported that
fluoride inhibits bone resorption [17], but his observa-
tion is still not uniformly accepted [18]. Pyrophospha-
tase activity is inhibited by fluoride in the presence of
excess magnesium (as in uremia) decreasing bone
mineralization [19, 20]. A further toxic effect of fluo-
ride on bone formation may relate to the fluoride
bonding with manganese, a cation necessary for glyco-
sylation, an intermediary step in the formation of col-
lagen [21]. Parathyroid hyperplasia and excess
parathyroid hormone secretion [22, 23] resulting from
fluoride accumulation may also contribute to bone de-
mineralization in renal failure by adding an additional
stimulus for secondary hyperparathyroidism.
Uremia and bemodialysis
Taves et a! were first to call attention to the "reverse
dialysis" of fluoride, resulting in net uptake of an esti-
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mated 10 mg of fluoride per hemodialysis [24].
Analysis of bone in a 41-yr-old woman treated with
hemodialysis using fluoridated water detected a fluo-
ride content of 5500 ppm, which was interpreted as
evidence suggesting that fluoride toxicity contributed
to the patient's bone disease. Taves and associates ex-
tended these observations by measuring fluoride up-
take at each hemodialysis, during which increases in
arterial and venous blood fluoride concentrations
occurred uniformly [10]. Net transfer of fluoride from
dialysate to blood (uptake) was found to be 3.4 moles/
mm.
In these studies dialysance of fluoride was calculated
by the formula proposed by Wolf et at [25]:
A-RDialysance = aA—u
whete A =arterial concentration, R venous or return
concentration, u = dialysate concentration and a
blood flow rate in mt/mm. Since fluoride concentration
in dialysate is higher than in blood, dialysance of
fluoride is positive even though the net flux is from
dialysate to blood. Dialysance of fluoride was 44 to
87 mt/mm for a Kiil dialyzer, and 82 to 99 ml/min for
a Kolif dialyzer; the higher dialysance during coil
(Kolif) dialysis was attributed to the higher dialysate
temperature in the coil system [10].
Confirmation of "reverse dialysis" of fluoride was
reported by Prosser et al [26], who demonstrated net
flux of '8F added to dialysate across the cellophane
membrane into blood, resulting in increased arterial
and venous 18F concentrations as a function of dura-
tion of dialysis. According to Prosser et al, fluoride up-
take was 14 to 20 mg per dialysis. Siddiqui et al [11]
calculated fluoride dialysance using a Kiil dialyzer as
80 mt/mm with blood flow of 200 mI/mm at a tem-
perature of 39°C. Net fluoride uptake per dialysis in
this study was 50 g/min or 30 mg per dialysis. Similar
findings were reported by Nielsen et al [13], who noted
a rise in arterial blood fluoride concentration from 9
3 moles to 19 4 moles after dialysis; the mean net
increase of blood fluoride concentration was 10±
3 moles per dialysis. In the study of Nielsen et al,
dialysance of fluoride in the Kiil dialyzer was 70
16 mI/mm at a blood flow of 200 ml/min at 37°C, a
finding consistent with other reports.
Siddiqui et a! [11] measured serum fluoride con-
centrations in the interdialytic period in anephric
patients in whom presumably there is no source for
excretion of F, and found that the immediate post-
dialysis increase in serum fluoride concentration is
followed by a subsequent fall in serum concentration.
The predialysis decrease in serum concentration was
attributed to transfer of fluoride from blood into bone.
Nielsen et al [13] administered '8F, i.v. and in dialysate,
confirming the almost exclusive uptake of fluoride by
bone. Total body bone scans provided further evidence
of the movement of fluoride from dialysate to blood
to bone [13].
In summary, the serum fluoride concentration is
elevated in uremic patients regularly dialyzed against
fluoridated water. Dialysis patients undergo progres-
sive retention of fluoride, which is probably deposited
almost exclusively in their bones.
Renal osteodystrophy is a very common complica-
tion in patients treated with maintenance hemodialysis.
Because of the many effects of fluoride on bone, several
groups have attempted to discern a correlation between
hyperiluoridemia and development of bone disease.
Osteosclerosis and osteoporosis
Kaye et at [27] described three uremic patients with
osteoscierosis in whom bone fluoride concentrations
were 2 to 5000 ppm in ashed bone [27]. The distribu-
tion of sclerotic lesions differed from that described in
classical fluorosis, a finding considered to be evidence
against the causal role of fluoride. As already men-
tioned herein, Taves et at in 1965 [24] suggested the
possible etiologic role of fluoride in the production of
bone disease in dialysis patients. Supportive of the thesis
of Taves Ct al, Posen et at [28] deduced that fluoride may
have worsened renal osteodystrophy in their patients
hemodialyzed with fluoridated water. In a subsequent
study, Taves et al suggested [10] that accumulated
fluoride in dialysis patients is likely to result in altered
bone formation, and that further studies were needed.
Siddiqui et at [11] provided further evidence of the
association between fluoride accumulation during the
course of maintenance hemodialysis complicated by
clinical bone disease. Serum fluoride concentrations
were highest in those patients who had been receiving
dialysis longest and there was a significant correlation
between the severity of bone disease and elevated
serum fluoride concentration. In 17 patients, bone
biopsy specimens were examined histologically. The
highest fluoride concentration was present in patients
who had radiologic osteomalacia and osteitis fibrosa
associated with histologic increase in total bone mass
and osteoid and decreased mineralized bone.
Kim et al [29] demonstrated that in patients with
advanced renal disease, fluoride content of cortical
hard bone is significantly greater than in patients with-
out renal or other bone disease. At variance with the
inference drawn from the work of Siddiqui et al [11],
Kim and co-workers did not discern a significant dif-
ference in bone fluoride concentration between uremic
patients treated and not treated with hemodialysis.
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Bone fluoride content in the study of Kim et a! was
similar whether osteoporosis, osteomalacia or osteitis
fibrosa was the principal lesion. However, bone con-
tent of calcium and phosphorus was lowest, and the
ratio of fluoride to calcium was highest in dialysis
patients.
Confirmation of the correlation of bone fluoride
concentration with both duration of hemodialysis and
histologic and radiologic evidence of osteodystrophy
was provided by Posen, Marier and Jaworski [30],
who found bone fluoride concentration in iliac crest
biopsy specimens as high as 22,700 ppm. In their study
of ionic composition of bone from uremic patients,
treated or not treated by hemodialysis, Parsons et at
[311 demonstrated uneven distribution of fluoride
throughout the skeleton and concluded that collection
of fluoride was probably responsible for some of the
increased osteoid seen in bone biopsy specimens. It
was hypothesized that bone containing fluoride may be
resistant to parathyroid hormone-induced bone re-
sorption, representing an unexpected advantage of
fluoride accumulation in dialysis patients susceptible
to secondary hyperparathyroidism.
At variance with their earlier study, Siddiqui
et a! in 1971 [12] compared bone disease in patients
in Birmingham, England, where symptomatic
osteodystrophy is uncommon and associated with
osteitis fibrosa, with patients in Newcastle, where
osteodystrophy is common and associated with
multiple fractures without radiological evidence of
osteitis fibrosa. Incrimination of fluoride in tap water
as a cause of the severe bone disease was not possible.
Speculation as to the presence of some other toxic
solute (unidentified) was the best available explanation
for the differing attack rates of bone disease.
Jowsey et al [32] studied the effect of low ( 5 mgI
100 ml) and high (6.0 mg/100 ml) dialysate calcium
concentration on bone disease. Two patients in each
group were dialyzed against high fluoride dialysate( 30 imoles) and five in each group against low
fluoride dialysate ( 10 moles). Though it was not
clear whether the use of high fluoride dialysate was
harmful or beneficial, there was nine times greater
osteoid formation and increased bone F/Ca ratio, and
increased osteoid width, in patients treated with high
fluoride dialysate. Four patients who were dialyzed
with high fluoride dialysate (30 imoles) suffered the
most disabling bone pain, muscle weakness and spon-
taneous fractures. These workers inferred that pro-
longed exposure to fluoride in dialysate can contribute
to bone disease in long-term hemodialysis patients
[32].
On the other hand, Nielsen et al [13], in an evalua-
tion of the effect of fluoridated water on dialysis
patients in Brooklyn, New York, noted increased al-
kaline phosphatase activity and increased radiographic
evidence of osteodystrophy consequent to dialysis with
fluoridated water. Because some patients dialyzed for
over five years had no evidence of osteodystrophy,
Nielsen et a! concluded that the use of fluoridated
water for dialysis is not universally associated with
osteodystrophy. Partial acquittal of fluoride as an in-
ducer of bone disease in dialysis patients may be in-
ferrable from the double-blinded study of Oreopoulos
et a! [33], who over 21 months of comparison of the
addition of fluoride to dialysate, were unable to show
a contributory role of fluoride in the progression of
osteomalacia, provided that serum calcium and phos-
phorus concentration were "adequately" controlled.
Directly at variance with the suggested benignity of
dialysate fluoride is the experience of Cordy et al [34],
who feel that fluoride in dialysate leads to osteo-
malacia, which is preventable by fluoride removal.
These conflicting results might be related to the shorter
duration of study by Oreopoulos Ct al.
Consistent with the thesis that fluoride causes pre-
ventable bone disease is the important report of Posen
et al [34], who compared the incidence of osteodys-
trophy in patients dialyzed with deionized and un-
treated water. Deionization not only prevented
development of symptomatic osteomalacia, but also
promoted healing of prior osteomalacia. Because
fluoride and other elements are removed by deioniza-
tion of water, the authors suggest that fluoride may
contribute to the development of osteomalacia. Ex-
hausted deionizer cartridges are potentially hazardous,
releasing very high concentrations of fluoride [36].
Discussion
Reflection upon the conflicting data pertaining to
the role of fluoride in the causation of metabolic bone
disease in dialysis patients leads to the conclusion that
the issue must be judged to be unsettled. Ever since
Roholm's initial description of bony changes due to
fluoride [37], the role of fluoride in producing bone
disease and other toxicities in otherwise normal popu-
lations has led to strongly partisan debate [39—40].
In uremia, where complex pathophysiologic pro-
cesses due to retained phosphorus, depressed serum
calcium concentration, impaired formation of 1.25
(OH)2D3, excess parathyroid hormone concentration,
trace metal accumulation and impaired collagen syn-
thesis all compromise the integrity of bone, any added
significance of fluoride accumulation is difficult to
evaluate. That some patients may be dialyzed with
fluoridated water for a decade without manifesting
bone pain or radiologic evidence of disease [13] does
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not vouchsafe the presence of fluoride in dialysate for
others.
Based on available indisputable studies showing
progressive increase in bone fluoride concentration as
a function of duration of dialysis (with fluoride-con-
taining dialysate), deployment of inexpensive deioni-
zers for tap water treatment seems a sensible precau-
tion at present. While it may take another decade to
prove or disprove the pathogenetic contribution of
fluoride to uremic bone disease, the desire to provide
currently dialyzed patients with an approximately nor-
mal internal milieu is sufficient reason to justify simple
and inexpensive water treatment to prevent fluoride
intoxication.
Factors other than fluoride influencing the indivi-
dual patient's probability of developing bone disease
during dialytic therapy include differences in dietary
calcium intake and degree of compliance with pre-
scribed regimens for control of serum phosphorus by
intraluminal gut binding. A controlled long-term pro-
spective study of metabolic bone disease during dialysis
with fluoride in dialysate as the only variable would
add important information to our still imprecise un-
derstanding of the complexities of bone disease in
uremia.
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